2 completed, 1 recruiting, 1 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Sparrow Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clofutriben Pharmacokinetics in Patients With Impaired Renal Function 12mg clofutriben - Moderate Renal Impairment | Phase 1 | Recruiting | Sparrow Pharmaceuticals | 16 | 2025-11-30 | 2025-12-23 |
| Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone midazolam, clofutriben once daily for 16 days, 2 single oral doses of prednisolone - Healthy Participants | Phase 1 | Completed | Sparrow Pharmaceuticals | 16 | 2025-10-03 | 2026-07-08 |
| A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) Prednisolone, SPI-62 - Polymyalgia Rheumatica | Phase 1 | Terminated | Sparrow Pharmaceuticals | 1 | 2022-02-22 | 2025-05-16 |
| A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 SPI-62, Cortisone-d8 - Type 2 Diabetes Mellitus in Obese, Obesity | Phase 1 | Completed | Sparrow Pharmaceuticals | 12 | 2021-07-23 | 2024-04-22 |
Obesity (1) · Polymyalgia Rheumatica (1)
Anti-Inflammatory Agents (1) · Glucocorticoids (1) · Midazolam (1) · Prednisolone (1)
United States (3) · Germany (1)
David Katz (1) · David Katz, PhD (1)